Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Stavisky RC, Watson SL, Anthony MS, Manuck SB, Adams MR, Kaplan JR. Influence of estradiol on cortisol secretion in ovariectomized cynomolgus macaques (Macaca fascicularis). Am J Primatol. 2003 May;60(1):17-22.
Stavisky RC, Ayers MR, Anthony MS, Hopkins WD, Andrews M, Kaplan JR. Assessment of cognitive performance in reproductively intact and ovariectomized monkeys. Am J Primatol. 1999;49(1):103.
Williams JK, Anthony MS, Clarkson TB. Coronary heart disease in rhesus monkeys with atherosclerosis. Poster presented at the 14th Annual Meeting of the American Society of Primatologists; June 1991. Veracruz, Mexico. [abstract] Am J Primatol. 1991 Jun; 24(2):140.
Miller LC, Anthony MS, Weingand KW, Clarkson TB. Development of nonhuman primate resource for atherosclerosis research. Poster presented at the Seventh Annual Meeting, American Society of Primatologists; June 1985. Niagara Falls, NY. [abstract] Am J Primatol. 1985 Jun; 8(4):353.